_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
The company has been manufacturing masks since the Covid-19 outbreak in 2020
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon has reported consolidated financial results for the period ended December 31, 2021
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
It provides Covid-19 detection and Omicron surveillance in less than two hours
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
This surpasses the number of approvals supported in 2020
Ind-Ra expects revenue growth of over 12% in 2022.
Subscribe To Our Newsletter & Stay Updated
